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Fibroblast Growth Factor Receptor 3 Mutations in
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Tumors
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and Francisco X. Real1,6
Epidermal nevi (EN) are benign lesions presenting at birth or in childhood. Based on the occurrence of
fibroblast growth factor receptor 3 (FGFR3) mutations in seborrheic keratosis and urothelial carcinomas (UC),
and the identification of two young patients with EN and UC, we hypothesized that mutations might occur in
EN. The R248C mutation was found in 6/23 (26.1%) EN but it was absent from unaffected skin. In two patients
with EN and UC, both lesions were FGFR3 wild type. Our findings indicate that: (1) FGFR3 mutations occur in
mosaicism and can cause EN and (2) other genes are involved in EN.
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INTRODUCTION
Epidermal nevi (EN) are a heterogeneous group of congenital
hamartomas characterized by hyperplasia of the epidermis
and adnexal structures and manifested by verrucoid scaly
plaques often following Blaschko’s lines. EN are distin-
guished by clinical, histopathological, and genetic criteria
(Happle and Rogers, 2002). EN can be associated with
complex developmental abnormalities (EN syndrome) and,
occasionally, with cutaneous squamous and basal cell
carcinomas (Sugarman, 2004).
Recently, activating fibroblast growth factor receptor 3
(FGFR3) mutations were reported in 39% of seborrheic
keratoses (Logie et al., 2005) and in 86% of adenoid
seborrheic keratosis (Hafner et al., 2006a). The highest
prevalence of somatic FGFR3 mutations occurs in urothelial
carcinomas (UC) (Cappellen et al., 1999). Mutations are
associated with low grade tumors (Billerey et al., 2001) with
an overall good prognosis (van Rhijn et al., 2003; Hernandez
et al., 2006). The same mutations have been reported in
germline DNA of patients with skeletal dysplasias (Horton
and Lunstrum, 2002). In UC and in skeletal dysplasias,
mutations occur mainly in hotspots in exons 7, 10, and 15
(Cappellen et al., 1999; Hernandez et al., 2006). Mutations
confer constitutive kinase activity and there is a good
correlation between the latter and disease severity (Naski
et al., 1996).
We have identified a 41-year-old patient with a congenital
widespread non-epidermolytic keratinocytic EN; lesions were
distributed in a checkerboard pattern. The patient had had a
low grade UC diagnosed at age 19. There were no skeletal
abnormalities and no family history of skin or urological
diseases. Three additional literature reports of EN and UC
were identified (Rosenthal and Fretzin, 1986; Rongioletti and
Rebora, 1991; Garcia de Jalon et al., 2004). Based on the
histological similarity of seborrheic keratosis and EN, and
these case reports, we hypothesized that FGFR3 mutations
might cause EN.
RESULTS
Characteristics of cases and mutational results are shown in
Table 1. In six patients (26.1%), the R248C mutation in exon
7 was found. Exons 10 or 15 were normal in all cases.
Mutations were not associated with gender, age at diagnosis,
location, number of EN, or histological subtype. Unaffected
skin from two patients with FGFR3mut EN showed FGFR3wt
sequences.
FGFR3 has been shown to be overexpressed in UC
(Gomez-Roman et al., 2005). Using immunohistochemistry,
FGFR3 was weakly detected in the basal cell layer of 2/6
FGFR3mut and 9/13 FGFR3wt samples of EN, similar to its
weak detection in normal epidermis. In the remaining
samples, FGFR3 was undetectable. No sample showed
evidence of increased FGFR3 expression.
We analyzed the TaG1 UC of two very young patients
with an associated EN. Both tumors were wild type for exons
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7 and 10–18; the corresponding patient’s EN were also
FGFR3wt.
DISCUSSION
Our results indicate that mutations in FGFR3 occur frequently
in EN. The characteristic distribution of lesions and absence
of mutations in unaffected skin indicate somatic mosaicism.
FGFR2 mutational somatic mosaicism in acne has also been
described (Munro and Wilkie, 1998).
While this paper was prepared, FGFR3 mutations were
reported in 16/39 (41%) EN from 11/33 (33%) patients. In all
but one case, the R248C substitution was found; in the
remaining case, two mutations (G372C and G382R) were
detected in exon 10. In four patients with an FGFR3mut EN,
unaffected epidermis adjacent to the nevus was FGFR3wt,
indicating mosaicism. In an additional case, leukocyte DNA
was FGFR3wt, supporting the lack of germline mutation
(Hafner et al., 2006b). Our findings provide strong support to
these data and suggest that other genes may contribute to the
development of EN, and to UC as well. PIK3CA mutations are
associated with low grade UC (Lopez-Knowles et al., 2006),
thus making it a candidate gene. A comparison of skin and
urothelium – and of benign and malignant lesions from these
epithelia – may provide important clues as to the genetic
mechanisms involved in tumor development and progression
in these tissues. This notion is supported by the known
involvement of PTCH and TSC1 alterations in both skin and
bladder tumors (Aboulkassim et al., 2003; Knowles et al.,
2003).
The role of mosaicism in tumor development is best
assessed in the skin because of its accessibility. It is tempting
to speculate that somatic mutations occurring in mosaicism
may also contribute to tumors in other tissues (i.e. bladder).
This concept, which could account for the association of EN
with UC, merits further analysis in human cancer biology.
MATERIALS AND METHODS
We retrieved and reviewed 23 EN showing ‘‘common’’ histopatho-
logical features, acrokeratosis verruciformis-like findings, or a
seborrheic keratosis-like pattern. In addition, the UCs of the case
described here and of an earlier report (Garcia de Jalon et al., 2004)
were analyzed. Informed consent was obtained from patients. The
study was approved by the Ethics Committee of Institut Municipal
d’Investigacio´ Me`dica and was conducted according to the
Declaration of Helskinki Principles. Microdissection, DNA extrac-
tion, primers, and PCR amplification of FGFR3 exons 7, 10, and 15
were performed as reported elsewhere (Hernandez et al., 2006);
exons 11–18 were also analyzed in DNA from the UC. All abnormal
sequences were independently confirmed.
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